Post-Trial Access to ATH434 for Patients With Multiple System Atrophy
ConditionMultiple System Atrophy
Trial statusAvailable
Trial phaseNot listed
Trial typeExpanded Access
Biological sexAll
AgeNot listed
SponsorAlterity Therapeutics
This multicenter post-trial access program is designed to provide ATH434 orally BID to eligible patients who completed Phase 2 studies ATH434-201 or ATH434-202, and who may benefit from this treatment according to the evaluation by their treating physicians.
Completed Alterity protocol ATH434-201 or ATH434-202
Expected to benefit from treatment from treatment with ATH434, in the opinion of the treating physician
Discontinued prior ATH434 treatment (ATH434-201 or ATH434-202) for any reason
Significant medical or psychiatric condition that may decrease the benefit-risk ratio of participation in this program to an unacceptable level, as per the treating physician's opinion